What are Ki‑67 hotspots in subcutaneous panniculitis‑like T‑cell lymphoma and how are they identified?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ki-67 Hotspots in Subcutaneous Panniculitis-Like T-Cell Lymphoma

Ki-67 hotspots are focal areas within tissue specimens where there is a high concentration of proliferating cells, specifically identified as regions enriched with atypical CD8+ cytotoxic T cells that show elevated Ki-67 staining (typically 50-90%), and these hotspots are characterized by adipocyte rimming by these proliferating lymphocytes—a finding highly specific for distinguishing SPTCL from lupus erythematosus panniculitis. 1, 2

Definition and Identification

Ki-67 hotspots represent discrete microscopic areas where proliferating tumor cells concentrate, creating regions of markedly increased Ki-67 immunoreactivity compared to surrounding tissue. 1

Key Identifying Features

  • Periadipocytic rimming pattern: The hotspots manifest as atypical lymphocytes surrounding individual adipocytes, with these rimming cells demonstrating strong Ki-67 nuclear positivity. 1, 3

  • High proliferation index: Within these hotspots, Ki-67 expression typically ranges from 50-90% of the atypical T cells, significantly higher than background lymphocytes. 2

  • Cytotoxic T-cell enrichment: The hotspots are specifically enriched with CD8+ T cells that co-express cytotoxic markers (TIA1, granzyme B) and show the characteristic adipotropic distribution. 1, 2

Diagnostic Methodology

Recommended Immunohistochemical Panel

A limited but highly effective panel includes: 1

  • Ki-67: To identify proliferation hotspots
  • CD3: Pan-T-cell marker
  • CD4: Typically negative in SPTCL
  • CD8: Highlights the cytotoxic T-cell population

Technical Assessment Approach

  • Dual-color immunohistochemistry: Ki-67/MART-1 or Ki-67/CD8 dual staining can specifically detect proliferation activity in the relevant cell population while excluding non-melanocytic or non-T-cell proliferating cells. 4, 5

  • Quantification method: Manual counting of at least 2000 cells in hotspot histological fields is recommended for accurate Ki-67 assessment, though the optimal standardized method remains under investigation. 4

  • Hotspot selection: Focus on areas where adipocyte rimming is most prominent and lymphocyte atypia is most evident. 1

Diagnostic Significance

Distinguishing SPTCL from LEP

The presence of Ki-67 hotspots is the single most useful feature for differentiating SPTCL from lupus erythematosus panniculitis. 1, 3

  • Sensitivity and specificity: Periadipocytic rimming with elevated Ki-67 demonstrates 79% sensitivity and 100% specificity for SPTCL versus LEP. 3

  • LEP lacks hotspots: Ki-67 hotspots are characteristically absent in lupus erythematosus panniculitis, making this a critical negative finding. 1

  • Combined criteria: Lymphocyte atypia combined with adipocyte rimming by CD8+ T cells within Ki-67 hotspots is highly specific for SPTCL diagnosis. 1

Clinical Context and Pitfalls

Important Caveats

  • Histologic overlap exists: Many features traditionally associated with LEP (hyaline lipomembranous change, B-cell aggregates, plasmacytoid dendritic cell clusters) can occur in SPTCL, including in patients who develop hemophagocytic lymphohistiocytosis. 1

  • Standardization challenges: Variable reproducibility and consistency across institutions exists for Ki-67 quantification, necessitating central pathology review when possible. 4

  • Specimen quality matters: Ki-67 staining may be limited by poor specimen quality or inadequate tissue sampling, requiring proper fixation (neutral buffered formalin for 4-48 hours) and adequate biopsy depth to capture subcutaneous tissue. 4, 5

Clinical Implications

  • Prognostic importance: SPTCL carries significant morbidity risk, with 37.5% of patients developing hemophagocytic syndrome in one series, making accurate diagnosis critical. 2, 6

  • Treatment differs: While SPTCL may respond to immunosuppressive therapy (oral steroids with or without low-dose methotrexate or cyclosporine A achieving 85% complete response), accurate distinction from LEP guides appropriate management. 6

  • Molecular confirmation: When Ki-67 hotspots are equivocal or histology shows significant overlap with LEP, T-cell receptor gene rearrangement studies can confirm monoclonality (found in 50% of SPTCL cases). 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.